# A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of HSK46256 in Patients With Advanced Solid Tumors

> **NCT07695142** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 275 (estimated)

## Conditions studied

- Advanced Solid Tumor (Phase 1)

## Interventions

- **DRUG:** HSK46256

## Key facts

- **NCT ID:** NCT07695142
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-09
- **Primary completion:** 2028-12-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 275 (ESTIMATED)
- **Last updated:** 2026-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07695142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07695142, "A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of HSK46256 in Patients With Advanced Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07695142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*